MRI developer Fonar of Melville, NY, has been issued another patent, this one for a novel software module designed to work with MRI scanners using multiple patient beds. The software is designed to increase the productivity of scanners using the
MRI developer Fonar of Melville, NY, has been issued another patent, this one for a novel software module designed to work with MRI scanners using multiple patient beds. The software is designed to increase the productivity of scanners using the multiple-bed configuration by allowing several scans to be conducted on the same machine simultaneously, according to a Fonar spokesperson.
MRI scanners in Fonar's new Quad line are open on all four sides, enabling patient beds to be attached to a scanner at any of the openings. Fonar last year received a patent for the technology (SCAN 4/24/96), which the company hopes will help it provide exams such as MRI breast screening at a cost of $80 to $150 per exam.
Last month's patent covers software that essentially allows the MRI scanner to keep up with the higher levels of throughput possible with the multiple-bed configuration, according to the spokesperson. It can, however, be used with all MRI scanners, not just the Quad line.
The software allows two or more patients to be scanned simultaneously, while a privacy shield can be installed in the scanner so that the patients feel they are receiving individual scans. The software should reduce scanner downtime and make MRI operation more efficient, according to Fonar.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.